Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Delayed Quote. Delayed  - 09/27 05:35:28 pm
95.66 EUR   +0.54%
09/26 MERCK : MilliporeSigma Launches Viresolve® Pro Shield H for More Rob..
09/22 MERCK : and the Royal Health Awareness Society Partner to Advance Wo..
09/21 MERCK : Invests over € 50 million in Flagship Pharmaceutical Packagi..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck KGaA : Effect Pigments for Architecture: Merck Exhibits at the Middle East Coatings Show 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2012 | 10:24am CEST

Darmstadt/Germany, March 5, 2012 - Merck will be presenting its effect pigments for architecture at the Middle East Coatings Show in Dubai from March 12 to 14, 2012. This exhibition is the most important platform for the coatings sector in the Middle East and the Gulf region. The focus of the exhibition will be on architectural applications, which have been seeing rapid growth in the region for the past several years. The trend toward gold and silver shades, which can currently be seen in lifestyle products and interior designs, is also being reflected in architecture.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
09/26 MERCK : MilliporeSigma Launches Viresolve® Pro Shield H for More Robust, Economi..
09/22 MERCK : and the Royal Health Awareness Society Partner to Advance Women's Health..
09/21 MERCK : Invests over € 50 million in Flagship Pharmaceutical Packaging Building ..
09/21 GLOBAL AZO PIGMENTS MARKET 2016 : Basf, Clariant, Lanxess, Eckart, EMD, Merck KG..
09/21 MERCK : Angola Receives 4 Million Praziquantel Tablets
09/20 MERCK : Prexton successfully completes phase 1 Parkinson's disease trial
09/19 MERCK : New Steritest™ Symbio Pump Accessories Enable Faster, Safer Steril..
09/16 MERCK : Presents New Data Examining Durable Efficacy with Investigational Cladri..
09/15 MERCK : Announces 2016 Recipients of € 1 Million Grant for Multiple Sclerosis In..
09/15 MERCK : Findings from Merck KGaA Broaden Understanding of Granular Matter Resear..
More news
Sector news : Specialty & Advanced Pharmaceuticals
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
09/27 Shire returns rights to Humira biosimilar to Momenta Pharma
08/19 ALPHA FROM EQUAL-WEIGHTING : A Look At Materials
08/10 Bristol's Opdivo Fall-Out Brings Others Into Play
08/05 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q2 2016 Results - Earnings Call T..
08/04 Merck KGaA reports Q2 results
Advertisement
Financials (€)
Sales 2016 15 041 M
EBIT 2016 3 285 M
Net income 2016 1 546 M
Debt 2016 10 800 M
Yield 2016 1,29%
P/E ratio 2016 25,18
P/E ratio 2017 21,84
EV / Sales 2016 1,54x
EV / Sales 2017 1,37x
Capitalization 12 297 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 104 €
Spread / Average Target 9,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA9.29%13 828
ABBVIE INC8.15%104 341
BIOGEN INC1.13%67 888
KYOWA HAKKO KIRIN CO L..-14.86%9 116
MALLINCKRODT PLC-4.73%7 658
JAZZ PHARMACEUTICALS P..-11.93%7 493
More Results